-
Product Insights
NewNet Present Value Model: Keros Therapeutics Inc’s KER-050
Empower your strategies with our Net Present Value Model: Keros Therapeutics Inc's KER-050 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Keros Therapeutics Inc’s KER-012
Empower your strategies with our Net Present Value Model: Keros Therapeutics Inc's KER-012 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-065 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-065 in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-065 in Obesity Drug Details: KER-065 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteoporosis Drug Details: KER-012 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Osteogenesis Imperfecta
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Osteogenesis Imperfecta report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Osteogenesis Imperfecta Drug Details: KER-012 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Systolic Heart Failure Drug Details: KER-012 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-065 in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-065 in Duchenne Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-065 in Duchenne Muscular Dystrophy Drug Details: KER-065 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KER-012 in Diastolic Heart Failure (HFpEF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KER-012 in Diastolic Heart Failure (HFpEF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KER-012 in Diastolic Heart Failure (HFpEF) Drug Details: KER-012 is...
-
Product Insights
KER Lepaud Solar PV Park
KER Lepaud Solar PV Park is a solar PV project located in Nouvelle-Aquitaine, France. The project is owned by Generale du Solaire and was developed by Centrale Solaire de Lepaud. The project came online in 2021. Empower your strategies with our KER Lepaud Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
NewNet Present Value Model: Keros Therapeutics Inc’s KER-047
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.